Brca1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
BRCA1 (Breast Cancer 1)
BRCA1 (Breast Cancer 1) is a tumor suppressor gene encoding a protein essential for homologous recombination (HR) DNA repair[1]. While classically associated with breast and ovarian cancer, recent research has revealed important roles for BRCA1 in neuronal survival and its dysfunction contributes to neurodegenerative diseases[2].
| Attribute | Value |
|---|---|
| Gene Symbol | BRCA1 |
| Full Name | BRCA1 DNA Repair Associated |
| Chromosomal Location | 17q21.31 |
| NCBI Gene ID | 672 |
| OMIM | 113705 |
| Ensembl ID | ENSG00000012048 |
| UniProt | P38398 |
BRCA1 is a key component of the DNA damage response machinery:
BRCA1 is expressed in most tissues with high expression in:
| Approach | Status | Description |
|---|---|---|
| PARP inhibitors | Approved (cancer) | Synthetic lethality in BRCA-deficient tumors |
| BRCA1 restoration | Research | Gene therapy approaches |
| DNA repair enhancement | Research | Supporting neuronal DNA repair |
BRCA1 plays a central role in homologous recombination (HR), the most accurate pathway for repairing DNA double-strand breaks (DSBs). The protein forms a complex with BRCA2 and PALB2 to facilitate RAD51 filament formation on single-stranded DNA ends, enabling strand invasion and repair synthesis. BRCA1 also participates in checkpoint activation through ATM-mediated phosphorylation, halting the cell cycle to allow for proper DNA repair before replication proceeds.
BRCA1 is a key component of the Fanconi anemia (FA) pathway, which coordinates repair of interstrand crosslinks (ICLs). The FA core complex, including BRCA1, activates the downstream repair machinery through monoubiquitination of FANCD2 and FANCI. Cells lacking functional BRCA1 are hypersensitive to ICL-inducing agents like mitomycin C and cisplatin.
Beyond DNA repair, BRCA1 influences gene expression through multiple epigenetic mechanisms:
The synthetic lethality between BRCA1 deficiency and PARP inhibition has been exploited therapeutically. PARP inhibitors (olaparib, rucaparib, niraparib) are FDA-approved for BRCA-mutated ovarian and breast cancers. Clinical trials are investigating their use in BRCA-associated pancreatic cancer and prostate cancer.
Resistance to PARP inhibitors develops through multiple mechanisms:
| Model | Phenotype | Key Findings |
|---|---|---|
| Brca1 knockout mice | Embryonic lethal | Essential for development |
| Conditional knockout | Tumor prone | Mammary tumors, lymphomas |
| Brca1 knock-in mutants | Variable | Hypomorphic alleles viable |
| Humanized models | Disease mimic | Patient-derived xenografts |
The study of Brca1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4(9):665-676. PMID:15343273 ↩︎
King MC, et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646. PMID:14576434 ↩︎
Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014;343(6178):1470-1475. PMID:24656531 ↩︎